IP Library Granted Patent US 10,201,496
Granted Patent B2
US 10,201,496 · App. 15/267,070 · Granted Feb 12, 2019

Short duration depot formulations

Inventors: Guohua Chen (Sunnyvale, CA); David T. Priebe (Bellevue, WA)
Assignee: Durect Corporation
A61K9/0024A61K9/0014A61K9/0019A61K9/06A61K31/445A61K38/27A61K47/10A61K47/14A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,496
App. No.
15/267,070
Granted
Feb 12, 2019
Kind
B2
Abstract

Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Claims (20)

1. A composition comprising:

(a) a polyorthoester having a weight average molecular weight ranging from about 3000 to about 10,000;

(b); and

(c) bupivacaine base or pharmaceutically acceptable salt thereof in an amount ranging from about 1 wt % to about 20 wt % of the composition,

wherein the ratio of polyorthoester to triacetin ranges from about 40:60 to about 75:25.

2. The composition of claim 1 , wherein the bupivacaine base or pharmaceutically acceptable salt thereof comprises bupivacaine base.

3. The composition of claim 1 , wherein the polyorthoester has a weight average molecular weight ranging from about 4000 to about 8000.

4. The composition of claim 2 , wherein the polyorthoester has a weight average molecular weight ranging from about 4000 to about 8000.

5. The composition of claim 1 , wherein the bupivacaine base or pharmaceutically acceptable salt thereof is present in an amount ranging from about 2 wt % to about 20 wt % of the composition.

6. The composition of claim 2 , wherein the bupivacaine base or pharmaceutically acceptable salt thereof is present in an amount ranging from about 2 wt % to about 20 wt % of the composition.

7. The composition of claim 3 , wherein the bupivacaine base or pharmaceutically acceptable salt thereof is present in an amount ranging from about 2 wt % to about 20 wt % of the composition.

8. The composition of claim 4 , wherein the bupivacaine base or pharmaceutically acceptable salt thereof is present in an amount ranging from about 2 wt % to about 20 wt % of the composition.

9. The composition of claim 1 , wherein the ratio of polyorthoester to triacetin ranges from about 50:50 to about 75:25.

10. The composition of claim 2 , wherein the ratio of polyorthoester to triacetin ranges from about 50:50 to about 75:25.

11. The composition of claim 3 , wherein the ratio of polyorthoester to triacetin ranges from about 50:50 to about 75:25.

12. The composition of claim 4 , wherein the ratio of polyorthoester to triacetin ranges from about 50:50 to about 75:25.

13. The composition of claim 5 , wherein the ratio of polyorthoester to triacetin ranges from about 50:50 to about 75:25.

14. The composition of claim 6 , wherein the ratio of polyorthoester to triacetin ranges from about 50:50 to about 75:25.

15. The composition of claim 7 , wherein the ratio of polyorthoester to triacetin ranges from about 50:50 to about 75:25.

16. The composition of claim 8 , wherein the ratio of polyorthoester to triacetin ranges from about 50:50 to about 75:25.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2018
From: CHEN, GUOHUA; PRIEBE, DAVID T.
To: ALZA CORPORATION
Reel/Frame 047871/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2018
From: ALZA CORPORATION
To: DURECT CORPORATION
Reel/Frame 047871/0093 →
Continuity (4)
Continuation 11278472 · Apr 3, 2006
Division 10606969 · Jun 25, 2003
Provisional Application 60391867 · Jun 25, 2002
Related Publication 20170087086A1 · Mar 30, 2017
Cited By (1)
US 12,433,877